Status:
COMPLETED
Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer
Lead Sponsor:
Eli Lilly and Company
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
Gemcitabine and anthracycline combination has shown encouraging activity as neoadjuvant chemotherapy in locally advanced breast cancer. An addition of sequential gemcitabine and cisplatin, also a high...
Eligibility Criteria
Inclusion
- Diagnosis of breast carcinoma
- No previous chemotherapy, with bidimensionally measurable locally advanced disease
- Adequate performance status (Karnofsky Performance Status \[KPS\] greater than or equal to 70), bone marrow reserves, hepatic, cardiac and renal functions.
Exclusion
- Inflammatory breast cancer
- Pregnancy and Breast-feeding
- Serious concomitant disorder or infection
- Previous cancer within the last 5 years or a second primary malignancy.
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT00191789
Start Date
February 1 2003
End Date
April 1 2009
Last Update
July 27 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this clinical trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT -5 hours, EST), or speak with your personal physician.
Pune, Maharashtra, India, 411001
2
For additional information regarding investigative sites for this clinical trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT -5 hours, EST), or speak with your personal physician.
Vellore, Tamil Nadu, India, 632004
3
For additional information regarding investigative sites for this clinical trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT -5 hours, EST), or speak with your personal physician.
Delhi, India, 110029